Watanabe, Mitsuru
Nakamura, Yuri
Isobe, Noriko
Tanaka, Masami
Sakoda, Ayako
Hayashi, Fumie
Kawano, Yuji
Yamasaki, Ryo
Matsushita, Takuya
Kira, Jun-ichi
Funding for this research was provided by:
Japan Society for the Promotion of Science (19K07995, 18H06214, 16H02657, 19H01045, 16K09694)
Japan Society for the Promotion of Science (19K21317, 18K07529, 19K07997)
Ministry of Health, Labour and Welfare (H29-Nanchitou (Nan)-Ippan-043)
Article History
Received: 29 February 2020
Accepted: 4 June 2020
First Online: 9 July 2020
Ethics approval and consent to participate
: The study received ethical approval from the Ethics Committee of Kyushu University (approval number 575–08) and written informed consent was obtained from all participants.
: Not applicable.
: MW received speaker honoraria and consultant fees from Novartis Pharma and received a research grant from JSPS KAKENHI (grant no. 19 K07995). YN received a grant and salary from Mitsubishi Tanabe Pharma, Bayer Yakuhin, Ltd. and Japan Blood Products Organization, received speaker honoraria from Novartis Pharma, and received a grant from JSPS KAKENHI (grant nos. 18H06214 and 19 K21317). NI received grant support from Mitsubishi Tanabe Pharma, Osoegawa Neurology Clinic, Bayer Yakuhin, Ltd. and Japan Blood Products Organization, and received a research grant from JSPS KAKENHI (grant no. 18 K07529). AS received grant support from Yazuya. YK received a grant from JSPS KAKENHI (grant no. 19 K07997). RY received honoraria from Biogen Japan and received a research grant from JSPS KAKENHI (grant no. 16 K09694). TM received speaker honoraria payments from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, and Biogen Japan. JK received consultant fees, speaking fees and/or honoraria from Novartis Pharma, Mitsubishi Tanabe Pharma, Boehringer Ingelheim, Teijin Pharma, Takeda Pharmaceutical Company, Otsuka Pharmaceutical, Astellas Pharma, Pfizer Japan, Sumitomo Dainippon Pharma, and Eisai, and is supported by grants from JSPS KAKENHI (grant nos. 16H02657 and 19H01045) and Health and Labour Sciences Research Grants on Intractable Diseases (H29-Nanchitou (Nan)-Ippan-043). MT and FH declare that they have no competing interests.